This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose
expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and
pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas. The
study design consists of Dose Escalation and Dose Expansion Cohorts. In the dose escalation
phase of the study, subjects will be enrolled into sequential dose levels. During dose
escalation, two possible schedules for administration of SL-279252 may be explored. The MTD
or MAD may be determined for either schedule. Based on accumulating data from the dose
escalation phase, including safety, PK, pharmacodynamic and anti-tumor activity, up to two
dose expansion cohorts may be opened. The primary objective of the expansion phase is to
further refine the safety and tolerability of SL-279252. The expansion cohorts will evaluate
one or two doses of SL-279252 using one selected schedule. At the end of dose escalation and
dose expansion, safety, PK, anti-tumor activity, and pharmacodynamic data will be reviewed to
identify the RP2D.
| Overal Status | Start Date | Phase | Study Type |
|---|---|---|---|
| Recruiting | March 26, 2019 | Phase 1 | Interventional |
Primary Outcome 1 - Measure: Safety profile of SL-279252 - Incidence of all treatment emergent adverse events
Primary Outcome 1 - Time Frame: From Day 1 to 90 days after Last Dose of SL-279252 (approximately 1 year)
Primary Outcome 2 - Measure: Maximum Tolerated Dose (MTD) of SL-279252
Primary Outcome 2 - Time Frame: From Day 1 to 90 days after Last Dose of SL-279252 (approximately 1 year)
Criteria:
Inclusion Criteria:
Participants are eligible to be included in the study only if all the following criteria
apply.
1. Subject has voluntarily agreed to participate by giving written informed consent in
accordance with ICH/GCP guidelines and applicable local regulations.
2. Subject has a histologically confirmed diagnosis of one of the following unresectable
locally advanced or metastatic malignancies: melanoma, non-small cell lung cancer
(squamous, adeno, or adeno-squamous), urothelial cancer, squamous cell carcinoma of
the head and neck, squamous cell cervical cancer, gastric or gastro-esophageal
junction adenocarcinoma, squamous cell carcinoma of the anal canal, squamous cell
carcinoma of the skin, renal cell cancer, Hodgkin's lymphoma, diffuse large B cell
lymphoma, and microsatellite instability high (MSI-H) or mismatch repair deficient
(MMRD) solid tumors excluding CNS malignancies. MSI and MMRD testing results as per
institution is acceptable.
3. Subject must have received, been intolerant to, or is ineligible for standard therapy
(per local guidelines and approvals) or have a malignancy for which there is no
approved therapy considered standard of care.
4. Age 18 years and older.
5. Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
6. Has measurable disease by iRECIST (solid tumors) or RECIL 2017 (lymphoma).
7. Has life expectancy of greater than 12 weeks.
8. Has adequate organ function.
9. Females of child bearing potential (FCBP) must have a negative serum or urine
pregnancy test within 72 hours of D1 of IP.
10. Male subjects with female partners must have azoospermia from a prior vasectomy or
underlying medical condition or agree to use an acceptable method of contraception
during treatment and for 30 days.
11. All AEs resulting from prior anti-cancer immunotherapy have resolved.
12. Recovery from toxicities from prior anti-cancer treatments including surgery,
radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
1. Has received more than two prior checkpoint inhibitor containing treatment regimens
(regimen refers to either monotherapy or combination immunotherapies).
2. Refractory to last checkpoint inhibitor therapy defined as disease progression within
3 months of treatment initiation.
3. Concurrent chemotherapy, immunotherapy, biologic or hormonal therapy is prohibited.
4. Use of corticosteroids or other immunosuppressive medication, current or within 14
days of D1 of IP.
Show More
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Name: Shattuck Labs
Role: Study Director
Affiliation: Shattuck Labs
Name: Lini Pandite, M.D.
Phone: 984-329-5231
Email: lpandite@shattucklabs.com
| Facility | Status | Contact |
|---|---|---|
| The Sarah Cannon Research Institute Nashville, Tennessee 37203 United States |
Recruiting |
Melissa L Johnson, MD Melissa.Johnson@sarahcannon.com |
| The University of Texas MD Anderson Cancer Center Houston, Texas 77030 United States |
Recruiting |
David S Hong, MD dshong@mdanderson.org |
| Leuven Cancer Institute Leuven, 3000 Belgium |
Not yet recruiting |
Patrick Schoffski, Prof. 32 16 346900 patrick.schoffski@uzleuven.be |
| Princess Margaret Cancer Center Toronto, Ontario M5G 1Z5 Canada |
Recruiting |
Lillian Siu, MD Lillian.Siu@uhn.ca |
| Vall d'Hebron Institut D' Oncologia Barcelona, 08035 Spain |
Not yet recruiting |
Irene Brana, MD ibrana@vhio.net |
